LENVIMA is a kinase inhibitor that is indicated:
Differentiated Thyroid Cancer (DTC)
• For the treatment of patients with locally recurrent or metastatic,
progressive, radioactive iodine-refractory differentiated thyroid cancer
(DTC).
Renal Cell Carcinoma (RCC)
• In combination with pembrolizumab, for the first line treatment of adult
patients with advanced renal cell carcinoma (RCC).
• In combination with everolimus, for the treatment of adult patients with
advanced renal cell carcinoma (RCC) following one prior antiangiogenic
therapy.
Hepatocellular Carcinoma (HCC)
• For the first-line treatment of patients with unresectable hepatocellular
carcinoma (HCC).
Endometrial Carcinoma (EC)
• In combination with pembrolizumab, for the treatment of patients with
advanced endometrial carcinoma (EC) that is not microsatellite
instability-high (MSI-H) or mismatch repair deficient (dMMR) who have
disease progression following prior systemic therapy in any setting and
are not candidates for curative surgery or radiation.
